Fig. 2

Evaluation of utility of the 13 candidate biomarkers for predicting ILD progression. (A, B) Heatmap and diagnostic values of 13 candidate biomarkers for predicting ILD progression in patients with IPF and excerpts on total POSTN. (C, D) The heatmap and diagnostic values of 13 candidate biomarkers for predicting ILD progression in patients with non-IPF-ILD and excerpts on CCL17. ILD progression was defined as > 10% of relative decline in %FVC, acute exacerbation, or death within a year. Differences between the candidate biomarker levels of patients with and without ILD progression were compared using the Mann–Whitney U test. The proteins marked in blue exhibited significant variability after adjustment with Bonferroni’s method. CCL, C-C motif chemokine ligand; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; POSTN, periostin